10-Q 1 tv478716_10-q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2017

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____.

Commission File No. 001-15975

REMEDENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		86-0837251
(State or Other Jurisdiction Of Incorporation or Organization)		(I.R.S. Employer Identification Number)

Zuiderlaan 1-3 bus 8, 9000 Ghent, Belgium		N/A
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code 011 32 9 241 58 80

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)
		Emerging grorth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of common shares of registrant’s stock outstanding as of November 14, 2017 was 19,995,969.

REMEDENT, INC.

FORM 10-Q INDEX

	Page Number

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Balance Sheets as of September 30, 2017 (Unaudited) and March 31, 2017	3
Consolidated Statements of Operations for the Three and Six Months Ended September 30, 2017 and September 30, 2016 (Unaudited)	4
Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2017 and September 30, 2016 (Unaudited)	5
Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2017 and September 30, 2016 (Unaudited)	6
Notes to Consolidated Financial Statements (Unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3. Quantitative and Qualitative Disclosures About Market Risk	18
Item 4. Controls and Procedures	18

PART II – OTHER INFORMATION
Item 1. Legal Proceedings	19
Item 1A. Risk Factors	19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3. Defaults Upon Senior Securities	19
Item 4. [Removed and Reserved.]	19
Item 5. Other Information	19
Item 6. Exhibits	20
Signature Page	21

PART I – FINANCIAL INFORMATION

Item 1.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	September 30, 2017			March 31, 2017
ASSETS		(unaudited)
CURRENT ASSETS:
Cash and cash equivalents	$	88,814		$	147,106
Accounts receivable, net of allowance for doubtful accounts of $181,176 at September 30, 2017 and $164,321 at March 31, 2017		992,701			943,251
Inventories, net		122,016			110,404
Prepaid expense		189,449			84,139
Total current assets		1,392,980			1,284,900

PROPERTY AND EQUIPMENT, NET		224,488			274,357
OTHER ASSETS
Investment in GlamSmile Asia Ltd		2,147,373			1,970,245
Investment in Condor Technologies (formerly MFI) (Note 3)		1,200,292			1,200,292
Total assets	$	4,965,133		$	4,729,794
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable	$	1,239,806		$	1,038,686
Accrued liabilities		360,368			441,250
Deferred revenue		47,822			72,235
Total current liabilities		1,647,996			1,552,171

EQUITY:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)		—			—
Common stock, $0.001 par value; (50,000,000 shares authorized, 19,995,969 shares issued and outstanding at September 30, 2016 and March 31, 2017 respectively)		19,996			19,996
Treasury stock, at cost; 723,000 shares outstanding at September 30, 2017 and March 31, 2017 respectively		(831,450	)		(831,450	)
Additional paid-in capital		24,906,269			24,906,269
Accumulated deficit		(19,857,573	)		(19,969,732	)
Accumulated other comprehensive (loss) (foreign currency translation adjustment)		(1,098,747	)		(1,114,234	)
Obligation to issue shares (Note 3)		97,500			97,500
Total Remedent, Inc. stockholders’ equity		3,235,995			3,108,349
Non-controlling interest		81,142			69,274
Total stockholders’ equity		3,317,137			3,177,623
Total liabilities and equity	$	4,965,133		$	4,729,794

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended September 30,						For the six months ended September 30,
	2017			2016			2017			2016

Net sales	$	678,694		$	609,964		$	1,470,033		$	1,225,913
Cost of sales		197,700			206,495			530,872			396,826
Gross profit		480,994			403,469			939,161			829,087
Operating Expenses
Research and development		221			—			1,860			7,691
Sales and marketing		240,057			114,532			479,205			269,716
General and administrative		262,290			308,880			447,797			527,800
Depreciation and amortization		24,671			40,851			49,315			81,439
TOTAL OPERATING EXPENSES		527,239			464,263			978,177			886,646
(LOSS) INCOME FROM OPERATIONS		(46,245	)		(60,794	)		(39,016	)		(57,559	)
OTHER INCOME (EXPENSES)
Equity income from investments		112,480			115,827			177,128			211,163
Interest expense		(9,987	)		(15,848	)		(11,871	)		(31,597	)
Interest / Other income		—			27			—			737
Other deductions		(292	)		(1,109	)		(2,216	)		(1,896	)
TOTAL OTHER INCOME		102,201			98,897			163,041			178,407
NET INCOME BEFORE TAXES AND NON-CONTROLLING INTEREST		55,956			38,103			124,025			120,848
PROVISION FOR INCOME TAXES					—						2,440
INCOME FROM CONTINUING OPERATIONS BEFORE NON-CONTROLLING INTEREST, NET OF TAX		55,956			38,103			124,025			123,288
NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTEREST		6,228			8,610			11,866			(7,620	)

NET INCOME ATTRIBUTABLE TO REMEDENT INC. COMMON SHAREHOLDERS	$	49,728		$	29,493		$	112,159		$	130,908

INCOME PER SHARE
Basic	$	0.00		$	0.00		$	0.01		$	0.01
Fully diluted	$	0.00		$	0.00		$	0.01		$	0.01
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic		19,995,969			19,995,969			19,995,969			19,995,969
Fully diluted		19,995,969			19,995,969			19,995,969			19,995,969

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited)

	For the three months ended September 30,				For the six months ended September 30,
	2017		2016		2017		2016
Net Income	$	49,728	$	29,493	$	112,159	$	130,908
OTHER COMPREHENSIVE INCOME (LOSS):
Foreign currency translation adjustment		21,073		2,911		15,486		(19,801	)
COMPREHENSIVE INCOME	$	70,801	$	32,404	$	127,645	$	111,107

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the six months ended September 30,
	2017			2016

CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	112,159		$	130,908
Adjustments to reconcile net income to net cash used by operating activities
Depreciation and amortization		49,315			81,439
Inventory reserve		59,429			(4,926	)
Allowance for doubtful accounts		16,855			(1,200	)
Equity investment		(177,128	)		(211,163	)
Changes in operating assets and liabilities:
Accounts receivable		(49,450	)		28,548
Inventories		(11,612	)		20,754
Prepaid expenses		(105,310	)		31,797
Accounts payable		201,121			75,512
Accrued liabilities		(80,882	)		(115,497	)
Deferred revenue		(24,413	)		(18,040	)
Net cash used by operating activities		(9,916	)		18,132
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment		(4,341	)		(28,910	)
Net cash used by investing activities		(4,341	)		(28,910	)
NET INCREASE (DECREASE) IN CASH		(14,257	)		(10,778	)
Effect of exchange rate changes on cash and cash equivalents		(44,035	)		13,910
CASH AND CASH EQUIVALENTS, BEGINNING		147,106			94,434
CASH AND CASH EQUIVALENTS, ENDING	$	88,814		$	97,566
Supplemental Information:
Interest paid	$	11,871		$	6,528
Income taxes paid	$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

REMEDENT, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

DESCRIPTION OF THE COMPANY AND BASIS OF PRESENTATION

The Company is a manufacturer and distributor of cosmetic dentistry products, including a full line of professional dental tooth whitening products which are distributed in Europe, Asia and the United States. The Company manufactures many of its products in Ghent, Belgium as well as outsourced manufacturing in its facility in Beijing, China. The Company distributes its products using both its own internal sales force and through the use of third party distributors.

In these notes, the terms “Remedent”, “Company”, “we”, “us” or “our” mean Remedent, Inc. and all of its subsidiaries, whose operations are included in these consolidated financial statements.

The Company’s financial statements have been prepared on an accrual basis of accounting, in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein.

These financial statements of the Company are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Despite the net profit for the accounting years ending March 31, 2017 and March 31, 2016, the accumulated losses of the past affect the financial situation of the Company. The continuation of the Company as a going concern is dependent upon the Company’s ability to continue to generate profitable operations. As of September 30, 2017 the Company had a working capital deficit of $255,017, and an accumulated deficit of $19,857,573. Additional funding may be required in order to support the Company’s operations and the execution of its business plan.

There can be no assurance that the Company will be successful in raising the required capital or that it will ultimately attain a successful level of operations. These risks, among others, are also discussed in ITEM 1A – Risk Factors in the Company’s annual report on Form 10-K filed on June 29, 2017 with the SEC.

The Company has conducted a subsequent events review through the date the financial statements were issued, and has concluded that there were no subsequent events requiring adjustments or additional disclosures to the Company's financial statements at September 30, 2017.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended March 31, 2017, except as may be indicated below:

The accompanying consolidated financial statements include the accounts of: Remedent N.V. (incorporated in Belgium) located in Ghent, Belgium, Remedent Professional, Inc. and Remedent Professional Holdings, Inc. (both incorporated in California and inactive), Glamtech-USA, Inc. (a Delaware corporation acquired effective August 24, 2008), Remedent N.V.’s 50 % owned subsidiary, Biotech Dental Benelux N.V., a Belgium private company located in Ghent, Remedent N.V.’s 51% owned subsidiary, GlamSmile Deutschland GmbH, a German private company located in Munich (effective March 31, 2014 this subsidiary is inactive) and Remedent N.V.’s 80 % owned subsidiary, GlamSmile Rome, an Italian private company located in Rome (effective March 31, 2014 this subsidiary is inactive).

Remedent N.V. owns 21.51 % of Glamsmile Dental Technology Ltd., a Cayman Islands company (“Glamsmile Dental”). The subsidiaries of Glamsmile Dental include: Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong, Beijing Glamsmile Technology Development Ltd., a 100% owned subsidiary or GlamSmile Asia, its 80% owned subsidiary Beijing Glamsmile Trading Co., Ltd. and its 98% owned subsidiary Beijing Glamsmile Dental Clinic Co., Ltd., including its 100% owned Shanghai Glamsmile Dental Clinic Co., Ltd., its 100% owned Guangzhou Dental Clinic Co., Ltd. and its 50% owned Whenzhou GlamSmile Dental Clinic Ltd., which are accounted for using the equity method after January 31, 2012 (see Note 3 – Long-term Investment).

Remedent, Inc. is a holding company with headquarters in Ghent, Belgium. Remedent Professional, Inc. and Remedent Professional Holdings, Inc. have been dormant since inception.

For all periods presented, all significant inter-company accounts and transactions have been eliminated in the consolidated financial statements and corporate administrative costs are not allocated to subsidiaries.

Interim Financial Information

The interim consolidated financial statements of Remedent, Inc. and Subsidiaries (the “Company”) are condensed and do not include some of the information necessary to obtain a complete understanding of the financial data. Management believes that all adjustments necessary for a fair presentation of results have been included in the unaudited consolidated financial statements for the interim periods presented. Operating results for the three and six months ended September 30, 2017, are not necessarily indicative of the results that may be expected for the year ended March 31, 2018. Accordingly, your attention is directed to footnote disclosures found in the Annual Report on Form 10-K for the year ending March 31, 2017, and particularly to Note 2, which includes a summary of significant accounting policies.

Warranties

The Company typically warrants its products against defects in material and workmanship for a period of 24 months from shipment.

A tabular reconciliation of the Company’s aggregate product warranty liability for the reporting periods is as follows:

	Six months ended September 30, 2017		Year ended March 31, 2017
Product warranty liability:
Opening balance	$	5,333	$	5,695
Accruals for product warranties issued in the period		547		—
Adjustments to liabilities for pre-existing warranties		—		(362	)
Ending liability	$	5,880	$	5,333

Based upon historical trends and warranties provided by the Company’s suppliers and sub-contractors, the Company has made a provision for warranty costs of $5,880 and $5,333 as of September 30, 2017 and March 31, 2017, respectively.

Computation of Earnings (Loss) per Share

Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income (loss) per common share attributable to common stockholders assuming dilution is computed by dividing net income by the weighted average number of shares of common stock outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.

On April 1, 2009, the Company adopted changes issued by the FASB to the calculation of earnings per share. These changes state that unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents (whether paid or unpaid) are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method for all periods presented. The adoption of this change had no impact on the Company’s basic or diluted net loss per share because the Company has never issued any share-based awards that contain non-forfeitable rights.

At each of September 30, 2017 and March 31, 2017, the Company had 19,995,969, shares of common stock issued and outstanding. At September 30, 2017 and March 31, 2017, the Company did not have any warrants outstanding but had 787,500 and 1,357,500 options outstanding respectively.

Further, pursuant to ASC 260-10-50-1(c), if a fully diluted share calculation was computed for the three and six month periods ended September 30, 2017 and September 30, 2016 respectively, it would have excluded all options respectively since the Company’s average share trading price during the three month and six month periods ended September 30, 2017 and September 30, 2016 were less than the exercise price of all options.

Conversion of Foreign Currencies

The reporting and functional currency for the consolidated financial statements of the Company is the U.S. dollar. The home currency for the Company’s European subsidiaries, Remedent N.V., Biotech Dental Benelux N.V.,GlamSmile Rome and GlamSmile Deutschland GmbH, is the Euro, for Glamsmile Asia Ltd., and its subsidiaries, the Hong Kong dollar and the Chinese Renmimbi (“RMB”) for Mainland China. The assets and liabilities of companies whose functional currency is other that the U.S. dollar are included in the consolidation by translating the assets and liabilities at the exchange rates applicable at the end of the reporting period. The statements of income of such companies are translated at the average exchange rates during the applicable period. Translation gains or losses are accumulated as a separate component of stockholders’ equity.

Comprehensive Income (Loss)

The Company’s only component of other comprehensive income is the accumulated foreign currency translation consisting of (loss) and gains of $15,486 and $(19,801) for the six months ended September 30, 2017 and 2016, respectively. These amounts have been recorded as a separate component of stockholders’ equity (deficit).

New Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (ASC 606). The standard, as subsequently amended, is intended to clarify the principles for recognizing revenue for U.S. GAAP by creating a new Topic 606, “Revenue from Contracts with Customers”. This guidance supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition”, and supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition—Construction-Type and Production-Type Contracts”. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. The new guidance is effective for fiscal years beginning after December 15, 2017, which, for the Company, means the fiscal year beginning April 1, 2018. The Company is currently evaluating the new guidance to determine the impact it will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases” (Topic 842). The FASB issued this update to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption of the standard is permitted. We are currently evaluating the impact of the adoption of this guidance on our consolidated financial statements, however, we do not expect the adoption will have a material increase in the assets and liabilities of our consolidated balance sheet.

The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no material effect is expected on the consolidated financial statements as a result of future adoption.

LONG-TERM INVESTMENTS

GLAMSMILE ASIA LTD.

Acquisition

Effective January 1, 2010 the Company acquired 50.98% of the issued and outstanding shares of Glamsmile Asia Ltd. (“Glamsmile Asia” or “Glamsmile”), a private Hong Kong company, with subsidiaries in Hong Kong and Mainland China, in exchange for the following consideration:

325,000 Euro (US$466,725). As of March 31, 2011 the full amount was paid.

250,000 shares of common stock to be issued during the fiscal year ended March 31, 2011 ($97,500 was recorded as an obligation to issue shares as at March 31, 2010). The parties have agreed that the shares will be issued during fiscal year ended March 31, 2015.

100,000 options on closing (issued);

100,000 options per opened store at closing (issued);

100,000 options for each additional store opened before the end of 2011 at the price of the opening date of the store;

Assumption of Glamsmile’s January 1, 2010 deficit of $73,302; and

Repayment of the founding shareholder’s original advances in the amount of $196,599. The balance of $196,599, recorded as due to related parties at March 31, 2010, is unsecured, non-interest bearing and has no specific terms of repayment other than it will be paid out of revenues from Glamsmile, as working capital allows. During the year ended March 31, 2011 a total of $101,245 was paid to the founding shareholder, leaving a balance due of $95,354 on June 27, 2011. As at March 31, 2012 the full amount was paid.

All options reside under the Company’s option plan and are five year options.

Also pursuant to the agreement, the Company granted irrevocable right to Glamsmile Asia to use the Glamsmile trademark in Greater China.

The Company acquired a 50.98% interest in GlamSmile Asia Ltd. (“GlamSmile Asia”) in order to obtain a platform in the Chinese Market to expand and introduce our GlamSmile Asia concept into the Chinese Market. In order to sell into the Chinese Market, an approval by Chinese Authorities is required, in the form of licenses. As GlamSmile Asia was already the owner of such licenses prior to the acquisition, this was an important advantage. We obtained control of GlamSmile Asia through the acquisition of the 50.98% interest and the appointment of our CEO as a Board member of GlamSmile Asia.

On January 30, 2014, the Company has sold a total of 2,500,000 ordinary shares of its investment in GlamSmile Dental Technology Ltd for $3,000,000 and recognized a gain on the sale in the amount of $1,582,597. As of March 31, 2014 the Company has received $1,850,000 and has recorded the balance of $1,150,000 as an amount receivable.

Effective March 31, 2014 the Company has retained a 21.51% ownership in GlamSmile Asia Ltd.

Deconsolidation

On January 28, 2012, the Company entered into a Preference A Shares and Preference A-1 Shares Purchase Agreement (“Share Purchase Agreement”) with Glamsmile Dental Technology Ltd., a Cayman Islands company and a subsidiary of the Company (“Glamsmile Dental”), Glamsmile (Asia) Limited, a company organized and existing under the laws of Hong Kong and a substantially owned subsidiary of Glamsmile Dental, Beijing Glamsmile Technology Development Ltd., Beijing Glamsmile Trading Co., Ltd., Beijing Glamsmile Dental Clinic Co., Ltd., and Shanghai Glamsmile Dental Clinic Co., Ltd., Gallant Network Limited, a shareholder of Glamsmile Dental (“Gallant”), and IDG-Accel China Growth Fund III L.P. (“IDG Growth”), IDG-Accel China III Investors L.P.(“IDG Investors”) and Crown Link Group Limited (“Crown”)(“IDG Growth, IDG Investors and Crown collectively referred to as the “Investors”), pursuant to which the Investors agreed to (i) purchase from the Company an aggregate of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental, which represents all of the issued and outstanding Preference A-1 Shares of Glamsmile Dental, for an aggregate purchase price of $2,000,000, and (ii) purchase from Glamsmile Dental an aggregate of 5,000,000 shares of Preference A Shares for an aggregate purchase price of $5,000,000.

Under the terms of the Share Purchase Agreement, the Company agreed (a) to indemnify the Investors and their respective affiliates for losses arising out of a breach, or inaccuracy or misrepresentation in any representation or warranty made by the Company or a breach or violation of a covenant or agreement made by the Company for up to $1,500,000, and (b) to transfer 500,000 shares of Glamsmile Dental owned by the Company to the Investors in the event of breach of certain covenants by the Company. In connection with the Share Purchase Agreement, the Company also agreed to enter into an Investor’s Rights Agreement, Right of First Refusal and Co-Sale Agreement, and Voting Agreement with the parties.

In addition, in connection with the contemplated transactions in the Share Purchase Agreement on January 20, 2012, the Company entered into a Distribution, License and Manufacturing Agreement with Glamsmile Dental pursuant to which the Company appointed Glamsmile Dental as the exclusive distributor and licensee of Glamsmile Veneer Products bearing the “Glamsmile” name and mark in the B2C Market in the People’s Republic of China (including Hong Kong and Macau) and Republic of China (Taiwan) and granted related manufacturing rights and licenses in exchange for the original issuance of 2,857,143 shares of Preference A-1 Shares of Glamsmile Dental and $250,000 (the receipt of which was acknowledged as an offset to payment of certain invoices of Glamsmile (Asia) Limited).

On February 10, 2012, the sale of the Preference A-1 Shares and the Preference A Shares was completed. As a result of the closing, the equity ownership of Glamsmile Dental, on an as converted basis, is as follows: 31.4% by the Investors, 39.2 % by Gallant, and 29.4% by the Company. Mr. De Vreese, our chairman, will remain as a director of Glamsmile Dental along with Mr. David Lok, who is the Chief Executive Officer and director of Glamsmile Dental and principal of Gallant. The Investors have a right to appoint one director of Glamsmile Dental, and accordingly the Board of Directors of Glamsmile Dental will consist of Mr. De Vreese, Mr. Lok and a director appointed by the Investors.

In conjunction with the transaction and resulting deconsolidation of Glamsmile Dental, the Company recorded a gain of $1,470,776, calculated as follows:

Consideration received	$	2,000,000
Fair value of 29.4% interest		2,055,884
Carrying value of non-controlling interest		1,117,938
Less: carrying value of former subsidiary’s net assets		(2,002,329	)
Goodwill		(699,635	)
Investment China & Hong Kong		(1,082	)
Rescission agreement Excelsior (Note 11)		(1,000,000	)
	$	1,470,776

For the six month periods ended September 30, 2017 and September 30, 2016 the Company recorded equity income of $177,128 and $211,163 respectively as “Other income” for its portion of the net income recorded by GlamSmile Dental Technology Ltd.

The following tables represent the summary financial information of GlamSmile Asia as derived from its financial statements and prepared under US GAAP:

Operating data:	Six months ended September 30, 2017		Six months ended September 30, 2016
Revenues	$	3,378,743	$	3,670,360
Gross profit		2,952,336		3,238,212
Income (loss) from operations		1,038,782		3,293,110
Net income	$	823,471	$	981,696

CONDOR TECHNOLOGIES (formerly Medical Franchises & Investments ("MFI"))

Effective March 31, 2013, the Company acquired 6.12 % of the issued and outstanding shares of Condor Technologies NV, a Belgium corporation ("Condor") in exchange for a cash prepayment of $314,778 that was made during the fiscal year ended March 31, 2012. The Company’s investment in 70,334 shares of Condor has been recorded at the fair value of $787,339 which is the quoted market price of approximately USD $11.19 (€8.70) per share. Because the investment is being recognized as an available-for-sale investment, an unrecognized profit of $399,188 (2016-loss of $27,724) has been recorded in accumulated other comprehensive income due to fair value per share at March 31, 2017, being $17.07 (€16,00) per share. Future unrealized gains and losses on the investment in Condor Technologies will also be recognized in other comprehensive income until realized.

Per ASC-320-10-25-1, investments in debt and equity securities that have readily determinable fair values and are not classified as trading or held-to-maturity securities, are classified as available-for-sale securities.

MFI NV has been founded to market an advance in dental technology which has the potential to replace the process of making mechanical impressions of teeth and bite structures with a digital/optical scan. During November 2016, the name of the Company MFI NV was changed and renamed to Condor Technologies NV.

CONCENTRATION OF RISK

Financial Instruments — Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade accounts receivable.

Concentrations of credit risk with respect to trade receivables are normally limited due to the number of customers comprising the Company’s customer base and their dispersion across different geographic areas. At September 30, 2017, five customers accounted for 79.06% of the Company’s trade accounts receivables, and two customers accounted for 68.83%. At September 30, 2016, five customers accounted for 67.35% of the Company’s trade accounts receivables, and two customers accounted for 51.72%. The Company performs ongoing credit evaluations of its customers and normally does not require collateral to support accounts receivable.

Purchases — The Company has diversified its sources for product components and finished goods and, as a result, the loss of a supplier would not have a material impact on the Company’s operations. For the six months ended September 30, 2017 the Company had five suppliers who accounted for 61.28% of accounts payable. For the six months ended September 30, 2016 the Company had five suppliers who accounted for 21.55% of accounts payable.

Revenues — For the six months ended September 30, 2017 the Company had five customers that accounted for 56.49% of total revenues. One of the five customers accounted for 33.27% of total revenues. For the six months ended September 30, 2016 the Company had five customers that accounted for 71.10% of total revenues. One of the five customers accounted for 44.92% of total revenues.

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company’s accounts receivable at period end were as follows:

	September 30, 2017			March 31, 2017
Accounts receivable, gross	$	1,173,877		$	1,107,572
Less: allowance for doubtful accounts		(181,176	)		(164,321	)
Accounts receivable, net	$	992,701		$	943,251

INVENTORIES

Inventories at period end are stated at the lower of cost (first-in, first-out) or net realizable value and consisted of the following:

	September 30, 2017			March 31, 2017
Raw materials	$	18,970		$	12,254
Components		138,702			132,741
Finished goods		603,177			544,813
		760,849			689,808
Less: reserve for obsolescence		(638,833	)		(579,404	)
Net inventory	$	122,016		$	110,404

PREPAID EXPENSES

Prepaid expenses are summarized as follows:

	September 30, 2017		March 31, 2017
Prepaid materials and components	$	161,330	$	13,023
VAT payments in excess of VAT receipts		6.755		44,842
Prepaid consulting		925		15,354
Prepaid rent		4,420		3,266
Other		16,019		7.654
	$	189,449	$	84,139

PROPERTY AND EQUIPMENT

Property and equipment are summarized as follows:

	September 30, 2017			March 31, 2017
Furniture and Fixtures	$	476,871		$	472,530
Machinery and Equipment		2,104,720			2,104,720
		2,581,591			2,577,250
Accumulated depreciation		(2,357,103	)		(2,302,893	)
Property & equipment, net	$	224,488		$	274,357

9.	LONG TERM DEBT

Secured Debt Agreement

On June 3, 2011, the Company obtained a loan in the principal amount of $1,000,000 (the “Loan”) from an unrelated private company, Excelsior Medical (HK) (“EM”). In connection with the Loan, the Company issued a promissory note, with a simple interest rate of 5% per annum, secured by certain assets of the Company (the “Note”). The maturity date of the Loan is June 3, 2014. Interest of $50,000 per annum is payable in cash on an annual basis.

Effective as of January 11, 2012, the Company entered into a Rescission Agreement with EM and Asia Best Healthcare Co., Ltd. Under the Rescission Agreement, the Company agreed to repay a total of $1,000,000 received under the Distribution Agreement, plus a simple interest rate of 5%, beginning on June 30, 2012, according to the following payment schedule: (i) $250,000 to be paid no later than June 30, 2012, (ii) $250,000 plus interest on June 30, 2012, (iii) $250,000 plus interest on December 31, 2012, and (iv) $250,000 plus interest on June 30, 2013. The Company also agreed to secure such obligations owed to EM with certain collateral of the Company. During the period ended December 31, 2012 a partial payment of $20,000 in interest has been made.

Final settlement agreements were re-negotiated with EM and Asia Best Healthcare Co, Ltd. During January 2017. The Company agreed to pay a total amount of $500,000 to EM as final settlement and simultaneously agreed to pay a total amount of $500,000 to Asia Best Healthcare co., Ltd as final settlement of the loan agreement. Both payments were executed on March 6, 2017 as final settlement.

10.

DUE TO RELATED PARTIES AND RELATED PARTY TRANSACTIONS

Transactions with related parties not disclosed elsewhere in these financial statements consisted of the following:

Compensation:

During the six month periods ended September 30, 2017 and 2016 respectively, the Company incurred $122,837 and $95,080 respectively, as compensation for all directors and officers.

All related party transactions involving provision of services or tangible assets were recorded at the exchange amount, which is the value established and agreed to by the related parties and reflects arms’ length consideration payable for similar services or transfers.

11.

ACCRUED LIABILITIES

Accrued liabilities are summarized as follows:

	September 30, 2017		March 31, 2017
Accrued employee benefit taxes and payroll	$	168,352	$	126,767
Accrued travel		5,880		5,333
Accrued VAT		1,958		5,009
Accrued audit and tax preparation fees		6,204		38,960
Reserve for warranty costs		5,880		5,333
Accrued consulting fees		122,500		120,000
Other accrued expenses		49,594		139,848
	$	360,368	$	441,250

12.

EQUITY COMPENSATION PLANS

As of September 30, 2017, the Company had two equity compensation plans approved by its stockholders (1) the 2004 Incentive and Non-statutory Stock Option Plan (the “2004 Plan”); and (2) the 2007 Equity Incentive Plan (the “2007 Plan”). The Company approved the 2004 Plan reserving 800,000 shares of common stock of the Company pursuant to an Information Statement on Schedule 14C filed with the Commission on May 9, 2005. Finally, the Company’s stockholders approved the 2007 Plan reserving 1,000,000 shares of common stock of the Company pursuant to a Definitive Proxy Statement on Schedule 14A filed with the Commission on October 2, 2007.

In addition to the equity compensation plans approved by the Company’s stockholders, the Company has issued options and warrants to individuals pursuant to individual compensation plans not approved by our stockholders. These options and warrants have been issued in exchange for services or goods received by the Company.

The following table provides aggregate information as of September 30, 2017 with respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance.

	2004 Plan				2007 Plan
	Outstanding Options		Weighted Average Exercise Price		Outstanding Options			Weighted Average Exercise Price

Options outstanding and exercisable March 31, 2017		357,500	$	0.96		1,000,000		$	1.21
Options expired		—				(570,000	)
Options outstanding and exercisable September 30, 2017		357,500	$	0.50		430,000		$	0.50
Exercise price range	$	0.50			$	0.50
Weighted average remaining life		1.47 years				1.47 years

A summary of the Company’s equity compensation plans approved and not approved by shareholders is as follows:

Plan Category

Number of

securities to

issued upon

exercise of

outstanding

options,

warrants

and rights

Weighted-average

exercise price of

outstanding

options

warrants and

rights

Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))

Equity Compensation Plans approved by security holders

787,500

0.50

1,175,000

Total

787,500

0.50

1,175,000

For the six month periods ended September 30, 2017 and September 30, 2016 the Company has not recognized any stock based compensation expense in the consolidated statement of operations. No stock options were granted or cancelled in the six month periods ended September 30, 2017 and September 30, 2016.

13.

SEGMENT INFORMATION

The Company’s only operating segment consists of dental products and oral hygiene products sold by Remedent Inc., Condor North America LLC., Remedent N.V., and Biotech Dental Benelux N.V. Our operations are primarily in Europe and Asia and 79% of our sales for the six months ended September 30, 2017 and 100% of our sales for the six months ended September 30, 2016 were generated from customers outside of the United States.

14.

COMMITMENTS

Real Estate Lease:

The Company leases an office facility of 5,187 square feet in Ghent, Belgium from an unrelated party pursuant to a nine year lease commencing September 1, 2008 at a base rent of €5,712 per month for the total location ($6,717 per month at September 30, 2017).

Secondly, the Company leases an office facility of 635 square feet in Brussels, Belgium from an unrelated party pursuant to a nine year lease commencing July 1, 2012 at a base rent of €969 per month for the total location ($1,140 per month at September 30, 2017).

Real Estate Lease and All Other Leased Equipment:

Minimum monthly lease payments for real estate, and all other leased equipment are as follows based upon the conversion rate for the (Euro) at September 30, 2017:

March 31, 2018		60,173
March 31, 2019		120,347
March 31, 2020		120,347
March 31, 2021		97,932
Balance		9,090
Total:	$	407,889

15.

FINANCIAL INSTRUMENTS

The FASB ASC topic 820 on fair value measurement and disclosures establishes three levels of inputs that may be used to measure fair value: quoted prices in active markets for identical assets or liabilities (referred to as Level 1), observable inputs other than Level 1 that are observable for the asset or liability either directly or indirectly (referred to as Level 2), and unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities (referred to as Level 3).

The carrying values and fair values of our financial instruments are as follows:

			September 30, 2017				March 31, 2017
			Carrying		Fair		Carrying		Fair
	Level		Value		Value		value		value
Cash		1	$	88,814	$	88,814	$	147,106	$	147,106
Accounts receivable		2	$	992,701	$	992,701	$	943,251	$	943,251
Long Term investment and advance - GlamSmile Dental Technology Asia		2	$	2,147,373	$	2,147,373	$	1,970,245	$	1,970,245
Long term investments and advances Condor		1	$	1,200,292	$	1,200,292	$	1,200,292	$	1,200,292
Deferred revenue		2	$	47,822	$	47,822	$	72,235	$	72,235
Accounts payable		2	$	1,239,806	$	1,239,806	$	1,038,686	$	1,038,686
Accrued liabilities		2	$	360,368	$	360,368	$	441,250	$	441,250

The following method was used to estimate the fair values of our financial instruments:

The carrying amount of level 1 and level 2 financial instruments approximates fair value because of the short maturity of the instruments.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level 3 financial assets also include certain investment securities for which there is limited market activity such that the determination of fair value requires significant judgment or estimation.

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no significant transfers between Level 1, Level 2, or Level 3 during the six month period ended September 30, 2017. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following table provides a reconciliation of the beginning and ending balances of the item measured at fair value on a recurring basis in the table above that used significant unobservable inputs (Level 3):

	Six month period ended September 30, 2017
Long term investments and advances:
Beginning balance	$	1,970,245
Gains (losses) included in net loss		177,128
Transfers in (out of level 3)		—

Ending balance	$	2,147,373

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

The discussion contained herein is for the three and six months ended September 30, 2017 and September 30, 2016. The following discussion should be read in conjunction with the Company’s consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017. In addition to historical information, this section contains “forward-looking” statements, including statements regarding the growth of product lines, optimism regarding the business, expanding sales and other statements. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of our products. In addition, actual results could vary materially based on changes or slower growth in the oral care and cosmetic dentistry products market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in the dental industry; unexpected difficulties in penetrating the oral care and cosmetic dentistry products market; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors. Factors that could cause or contribute to any differences are discussed in “Risk Factors” and elsewhere in the Company’s annual report on Form 10-K filed on June 29, 2015 with the Securities and Exchange Commission. Except as required by applicable law or regulation, the Company undertakes no obligation to revise or update any forward-looking statements contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017. The information contained in this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017 is not a complete description of the Company’s business or the risks associated with an investment in the Company’s common stock. Each reader should carefully review and consider the various disclosures made by the Company in this Quarterly Report on Form 10-Q and in the Company’s other filings with the Securities and Exchange Commission.

Overview

We specialize in the research, development, and manufacturing of oral care and cosmetic dentistry products. We are one of the leading manufacturers of cosmetic dentistry products in Europe. Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we design, develop, manufacture and distribute our cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia and the United States. We distribute our products using both our own internal sales force and through the use of third party distributors.

Results of Operations

Comparative detail of results as a percentage of sales is as follows:

	For the three months ended September 30,						For the six months ended September 30,
	2017			2016			2017			2016

NET SALES		100.00	%		100.00	%		100.00	%		100.00	%
COST OF SALES		29.13	%		33.85	%		36.11	%		32.37	%
GROSS PROFIT		70.87	%		66.15	%		63.89	%		67.63	%
OPERATING EXPENSES
Research and development		0.03	%		0.00	%		0.13	%		0.63	%
Sales and marketing		35.37	%		18.78	%		32.60	%		22.00	%
General and administrative		38.65	%		50.64	%		30.46	%		43.05	%
Depreciation and amortization		3.64	%		6.70	%		3.35	%		6.64	%
TOTAL OPERATING EXPENSES		77.68	%		76.11	%		66.54	%		72.33	%
INCOME (LOSS) FROM OPERATIONS		(6.81	)%		(9.97	)%		(2.65	)%		(4.70	)%
Other income		15.06	%		16.21	%		11.09	%		14.55	%
INCOME (LOSS) BEFORE INCOME TAXES		8.24	%		6.25	%		8.44	%		9.86	%
Income taxes		0.00	%		0.00	%		0.00	%		0.20	%
NET INCOME		8.24	%		6.25	%		8.44	%		10.06	%
NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTEREST		0.92	%		1.41	%		0.81	%		(0.62	)%
NET INCOME (LOSS) ATTRIBUTABLE TO REMEDENT INC. COMMON SHAREHOLDERS		7.33	%		4.84	%		7.63	%		10.68	%

Net Sales

Net sales increased by approximately 11.27% to $678,694 for the three months ended September 30, 2017 as compared to $609,964 for the three months ended September 30, 2016. The increase in sales is primarily due to our recent launch of our Condor 3D Scanner in the North American market.

Net sales increased by approximately 19.91% to $1,470,033 for the six months ended September 30, 2017 as compared to $1, 225,913 for the six months ended September 30, 2016. Net sales increased in the six months ended September 30, 2017 for the same reason as the three month variance.

Cost of Sales

Cost of sales decreased approximately 4.26% to $197,700 for the three months ended September 30, 2017 as compared to $206,495 for the three months ended September 30, 2016. Cost of sales, as a percentage of net sales, has decreased to 29.13% in the quarter ended September 30, 2017 as compared to 33.85% in the quarter ended September 30 2016.

Cost of sales increased approximately 33.78% to $530,872 or the six months ended September 30, 2017 as compared to $396,826 for the six months ended September 30, 2016. Cost of sales increased mainly because of increased sales.

Gross Profit

Our gross profit increased by $77,525 or 19.21% to $480,994 for the three months ended September 30, 2017 as compared to $403,469 for the three months ended September 30, 2016. Our gross profit as a percentage of sales increased to 70.87% in the three months ended September 30, 2017 as compared to 66.15% for the three months ended September 30, 2016.

Our gross profit increased by $110,074 or 13.28%, to $939,161 for the six months ended September 30, 2017 as compared to $829,087 for the six months ended September 30, 2016 primarily because of our initial launch of our 3D Scanner on the American market and increased sales in general.

Operating Expenses

Research and Development. Our research and development expenses increased to $221 for the three months ended September 30, 2017 as compared to zero for the three months ended September 30, 2016 an increase of 100.0%.

Our research and development costs decreased by $5,831 or 75.82% to $1,860 for the six months ended September 30, 2017 as compared to $7,691 for the six months ended September 30, 2016. Our research and development costs have decreased because of the finalization of our Software program the “Smile me Mirror”.

Sales and marketing costs. Our sales and marketing costs for the three months ended September 30, 2017 and 2016 were $240,057 and $114,532 respectively, representing an increase of $125,525 or 109.60%. The increase is largely due to increasing our sales staff.

Our sales and marketing costs increased by $209.489 or 77.67% to $479,205 for the six months ended September 30, 2017 as compared to $269,716 for the six months ended September 30, 2016 because of hiring new people for our sales force.

General and administrative costs. Our general and administrative costs for the three months ended September 30, 2017 and 2016 were $262,290 and $308,880 respectively, representing a decrease of $46,590, or 15.08%. Our general and administrative costs for the six months ended September 30, 2017 and 2016 were $447,797 and $527,800 respectively, representing a decrease of $46,590 or 15.08%. The decrease in general and administration costs is largely due to increased synergy between our internal divisions as a result of ongoing internal reorganization.

Depreciation and amortization. Our depreciation and amortization was $24,671 for the three months ended September 30, 2017 as compared to $40,851 for the three months ended September 30, 2016. Our depreciation and amortization was $49,315 for the six months ended September 30, 2017 versus $81,439 for the six months ended September 30, 2016. Our depreciation and amortization expense has decreased as a result of the life of our equipment.

Other income. Our net other income was $102,201 for the three months ended September 30, 2017 as compared to $98,897 for the three months ended September 30, 2016, an increase in other income of $3,304. The increase in other income was primarily because of decreased interest expense. Our net other income decreased by $15,366 to $163,041 for the six months ended September 30, 2017 as compared to $178,407 for the six months ended September 30, 2016, for the same reason as the three month variance.

Internal and External Sources of Liquidity

As of September 30, 2017, we had current assets of $1,392,980 compared to $1,284,900 at March 31, 2017. The increase of $108,080 was due to a decrease in cash of $58,292, offset by an incease in accounts receivable of $49,450, and increase in inventories of $11,612 and an increase in prepaid expenses of $105,310.

As of September 30, 2017, we had cash of $88,814. We anticipate that we will need to raise additional funds to satisfy our working capital requirements and implement our business strategy to expand our direct to consumer business model. We intend to continue to look for opportunities to expand the number of GlamSmile Studios in Europe. We will continue to review our expected cash requirements, make all efforts to collect any aged receivables, and take appropriate cost reduction measures to ensure that we have sufficient working capital to fund our operations. In the event additional needs for cash arise, we may seek to raise additional funds from a combination of sources including issuance of debt or equity securities. Additional financing may not be available on terms favorable to us, or at all. Any additional financing activity could be dilutive to our current stockholders. If adequate funds are not available or are not available on acceptable terms, our ability to take advantage of unanticipated opportunities or respond to competitive pressures could be limited.

Cash and Cash equivalents

Our balance sheet at September 30, 2017 reflects cash of $88,814 as compared to $147,106 as of March 31, 2017, a decrease of $58,292.

Operations

Net cash used by operations was $9,916 for the six months ended September 30, 2017 as compared to net cash provided by operations of $18,132 for the six months ended September 30, 2016. The increase of $28,048 in net cash used by operations for the six months ended September 30, 2017 as compared to the six months ended September 30, 2016 is primarily because of decreased income of $18,749, offset by the changes in operating assets and liabilities.

Investing activities

Net cash used in investing activities totaled $4,341 for the six months ended September 30, 2017 as compared to net cash used by investing activities of $28,910 for the six months ended September 30, 2016. Cash used in the six months ended September 30, 2017 and 2016 was primarily for investing in equipment.

Financing activities

During the six months ended September 30, 2017 and September 30, 2016, we recognized an increase/ (decrease) in cash and cash equivalents of ($44,035) and $13.910, respectively, from the effect of exchange rates between the Euro and the US Dollar.

Off-Balance Sheet Arrangements

At September 30, 2017, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized, and reported within the required time periods and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objective, and management is required to exercise its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Management conducted an evaluation, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2017. Based on this evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2017.

Changes in Internal Control Over Financial Reporting

There have been no material changes in our internal controls over financial reporting identified in connection with the evaluation of disclosure controls and procedures discussed above that occurred during the quarter ended September 30, 2017 or subsequent to that date that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

To the best knowledge of management, there are no material legal proceedings pending against the Company.

Item 1A. Risk Factors

Not Applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. [Removed and Reserved]

Item 5. Other Information

None.

Item 6. Exhibits

EXHIBIT INDEX

Exhibit No		Description

31.1*		Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act

31.2*		Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act

32.1*		Certifications of the Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act

32.2*		Certifications of the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase

101.DEF*		XBRL Taxonomy Extension Definition Linkbase

101.LAB*		XBRL Taxonomy Extension Label Linkbase

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	REMEDENT, INC.


Date: November 14, 2017	By:	/s/ Guy De Vreese
		Name: Guy De Vreese
		Title: Chief Executive Officer (Principal Executive Officer)

Date: November 14, 2017	By:	/s/ Philippe Van Acker
		Name: Philippe Van Acker
		Title: Chief Financial Officer (Principal Financial and Accounting Officer)